Wells Fargo & Company MN Purchases 17,094 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Wells Fargo & Company MN raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 220,123 shares of the company’s stock after acquiring an additional 17,094 shares during the quarter. Wells Fargo & Company MN’s holdings in CRISPR Therapeutics were worth $8,664,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. ExodusPoint Capital Management LP bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $1,883,000. Pictet Asset Management Holding SA increased its holdings in shares of CRISPR Therapeutics by 9.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 272,704 shares of the company’s stock worth $10,734,000 after purchasing an additional 22,414 shares in the last quarter. Norges Bank purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth $17,458,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of CRISPR Therapeutics by 166.3% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 36,264 shares of the company’s stock valued at $1,427,000 after purchasing an additional 22,647 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after purchasing an additional 372 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Down 0.0 %

NASDAQ:CRSP opened at $37.77 on Friday. The company has a market capitalization of $3.24 billion, a P/E ratio of -8.64 and a beta of 1.85. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The stock’s fifty day moving average is $40.97 and its two-hundred day moving average is $43.81.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, Director John Greene bought 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the acquisition, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of recent analyst reports. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Stifel Nicolaus dropped their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Finally, Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.